PT1894576E - Novo agente redutor dos níveis de triglicéridos - Google Patents

Novo agente redutor dos níveis de triglicéridos Download PDF

Info

Publication number
PT1894576E
PT1894576E PT06756590T PT06756590T PT1894576E PT 1894576 E PT1894576 E PT 1894576E PT 06756590 T PT06756590 T PT 06756590T PT 06756590 T PT06756590 T PT 06756590T PT 1894576 E PT1894576 E PT 1894576E
Authority
PT
Portugal
Prior art keywords
reducing agent
triglyceride reducing
novel triglyceride
novel
agent
Prior art date
Application number
PT06756590T
Other languages
English (en)
Inventor
Taro Aoki
Toru Yokoyama
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PT1894576E publication Critical patent/PT1894576E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PT06756590T 2005-06-08 2006-05-25 Novo agente redutor dos níveis de triglicéridos PT1894576E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68837905P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
PT1894576E true PT1894576E (pt) 2011-07-29

Family

ID=37498294

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06756590T PT1894576E (pt) 2005-06-08 2006-05-25 Novo agente redutor dos níveis de triglicéridos

Country Status (11)

Country Link
US (2) US20090227610A1 (pt)
EP (1) EP1894576B1 (pt)
JP (1) JP4892477B2 (pt)
KR (1) KR101258422B1 (pt)
CN (1) CN101193656B (pt)
CY (1) CY1111768T1 (pt)
ES (1) ES2362534T3 (pt)
HK (1) HK1111632A1 (pt)
PL (1) PL1894576T3 (pt)
PT (1) PT1894576E (pt)
WO (1) WO2006132091A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580818B2 (en) 2005-09-15 2013-11-12 Otsuka Pharmaceutical Co., Ltd. Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
RS53084B (en) 2006-07-05 2014-06-30 Takeda Gmbh COMBINATION OF HMG-COA ROSUVASTATIN REDUCTASE INHIBITOR WITH PHOSPHODIESTERASE 4 INHIBITOR, WHICH IS ROFLUMILAST, ROFLUMILAST-N-OXIDE FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
US20120108651A1 (en) * 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
CA2917780C (en) * 2013-07-25 2023-01-24 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
KR101920307B1 (ko) * 2017-04-28 2018-11-20 가톨릭대학교 산학협력단 고정용량의 실로스타졸 서방출 및 스타틴 일반방출 미니정제를 포함하는 1일 1회 경구복용 복합 캡슐제 및 이의 제조방법
CN113316469A (zh) * 2019-03-13 2021-08-27 国立大学法人浜松医科大学 主动脉瘤的治疗用医药组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2964029B2 (ja) * 1995-10-05 1999-10-18 大塚製薬株式会社 カルボスチリル誘導体
TW338037B (en) * 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
AU2404897A (en) * 1996-04-24 1997-11-12 Takeda Chemical Industries Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US20020055533A1 (en) * 2000-09-01 2002-05-09 Sankyo Company, Limited Pharmaceutical composition
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
CA2488499C (en) * 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
JP2007230883A (ja) * 2006-02-28 2007-09-13 Kowa Co 新規なマラリア原虫類による感染症の予防及び／又は治療剤

Also Published As

Publication number Publication date
CY1111768T1 (el) 2015-10-07
KR101258422B1 (ko) 2013-04-26
KR20080015789A (ko) 2008-02-20
CN101193656A (zh) 2008-06-04
WO2006132091A1 (ja) 2006-12-14
EP1894576A4 (en) 2010-04-21
EP1894576A1 (en) 2008-03-05
JPWO2006132091A1 (ja) 2009-01-08
US20090227610A1 (en) 2009-09-10
JP4892477B2 (ja) 2012-03-07
US20150272944A1 (en) 2015-10-01
CN101193656B (zh) 2011-03-02
ES2362534T3 (es) 2011-07-07
EP1894576B1 (en) 2011-05-25
PL1894576T3 (pl) 2011-10-31
HK1111632A1 (en) 2008-08-15

Similar Documents

Publication Publication Date Title
PL2175273T3 (pl) Środek nadający kokumi
HK1116776A1 (en) Triazolophthalazines as pde2-inhibitors
IL184421A0 (en) Fertilizer-compatible composition
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
GB0522658D0 (en) Composition
EP1950309A4 (en) ALBUMIN DENATURING AGENCY
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
GB0618435D0 (en) Composition
GB0506044D0 (en) Composition
GB0508250D0 (en) Composition
EP1847249A4 (en) hair dye
GB0507167D0 (en) Composition
EP1927347A4 (en) MEANS TO REDUCE BITTERNESS
EP1889660A4 (en) OZONE-GROWING AGENT
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
HK1111632A1 (en) Novel triglyceride reducing agent
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0502341D0 (en) Composition
GB0513641D0 (en) Anti-egeing composition
GB0613762D0 (en) Slabline structure
GB0510286D0 (en) Composition
EP1865313A4 (en) OPTICAL ISOMER SEPARATION AGENT
GB0512782D0 (en) Supports
GB0503644D0 (en) Catstep I
GB0520623D0 (en) Elevated structure